The clinical and financing milestones reduce near-term dilution risk. Next catalyst: PMA submission to FDA following 12-month data collection. Monitor for data readouts and regulatory updates.
Price Chart
Executive Summary
Envoy Medical reported Q1 2026 revenue of $39K, down 15% YoY, with an operating loss of $5.96M. The company highlighted completion of pivotal trial enrollment (56 patients), $30M gross capital raise, and early positive clinical data. Cash balance improved to $25.3M, extending runway through PMA submission.
Key Financial Metrics
Key Facts
- Q1 2026 net revenue $39K vs $46K in Q1 2025 (down 15% YoY)
- Operating loss widened to $5.96M from $5.11M
- Net loss per share improved to ($0.08) from ($0.29) due to higher share count
- Cash at March 31, 2026: $25.3M vs $3.7M at year-end 2025
- Pivotal clinical trial fully enrolled (56 patients); first 3 patients reached 12-month endpoint
- Completed $30M public offering (up to $78M with warrants) led by Nantahala Capital
- Six-month data showed CNC word recognition improvement (15.2% to 39.2%) and 24-hour wear time
- New board member Chas McKhann appointed in April 2026
Financial Impact
Revenue declined $7K (15% YoY); cash increased by $21.5M from capital raise
Risk Factors
- Revenue remains near-zero; fully dependent on regulatory approval of Acclaim CI
- Potential warrant exercise dilution if stock price stays below $11.50
- FDA approval not guaranteed; PMA review timeline uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-054185 |
| Document: ea0289965-8k_envoy.htm | 0001213900-26-054185 |
| Document: 0001213900-26-054185-index-headers.html | 0001213900-26-054185 |
| Document: 0001213900-26-054185-index.html | 0001213900-26-054185 |
| Document: 0001213900-26-054185.txt | 0001213900-26-054185 |
| 8-K Data (Synthetic) | 0001213900-26-054185 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 18, 2026 23w ago | 8-K | $0.0475 $0.0325 | ▼ −31.58% | ▼ −32.56% | — |
May 11, 2026 24w ago | 8-K | $0.0475 $0.0475 | · 0.00% | ▲ +0.30% | — |
Apr 17, 2026 27w ago | 3 | $0.0475 $0.0475 | · 0.00% | ▼ −4.20% | — |
Apr 13, 2026 28w ago | 10-K/A | $0.0475 $0.0475 | · 0.00% | ▼ −6.30% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers